Oxaliplatin-based hyperthermic intraperitoneal chemotherapy in primary or recurrent epithelial ovarian cancer: A pilot study of 31 patients

Journal of Surgical Oncology

Volumn 103, Issue 1, 2011, Pages 10-16

  Frenel, Jean Sebastien ^a   Leux, Christophe ^b   Pouplin, Luc ^a   Ferron, Gwenael ^c   Berton Rigaud, Dominique ^a   Bourbouloux, Emmanuelle ^a   Dravet, François ^a   Jaffre, Isabelle ^a   Classe, Jean Marc ^a  

^a CENTRE RENÉ GAUDUCHEAU   (France)

^b Cancer Registry of Loire Atlantique   (France)

^c INSTITUT CLAUDIUS REGAUD   (France)

Author keywords

cytoreductive surgery; HIPEC; ovarian carcinoma; oxaliplatin; peritoneal carcinomatosis

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; DOXORUBICIN; INTERFERON; MITOMYCIN; MITOXANTRONE; OXALIPLATIN; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL ARTICLE; CYTOREDUCTIVE SURGERY; DRUG SAFETY; FEASIBILITY STUDY; FEMALE; HUMAN; HYPERTHERMIC THERAPY; HYPOKALEMIA; INTENSIVE CARE UNIT; INVASIVE PROCEDURE; LENGTH OF STAY; MORBIDITY; MULTIPLE CYCLE TREATMENT; OVARY CANCER; PERITONEAL CARCINOMATOSIS INDEX; PILOT STUDY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RATING SCALE; RECURRENT CANCER; REOPERATION; SURGICAL MORTALITY;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA; FEASIBILITY STUDIES; FEMALE; HUMANS; HYPERTHERMIA, INDUCED; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, GLANDULAR AND EPITHELIAL; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; PILOT PROJECTS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 78650649984     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.21732     Document Type: Article

References (52)

1. Kyrgiou M, Salanti G, Pavlidis N, et al.: Survival benefits with diverse chemotherapy regimens for ovarian cancer: Meta-analysis of multiple treatments. J Natl Cancer Inst 2006; 98: 1655-1663.
2. Alberts DS, Green S, Hannigan EV, et al.: Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: Final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer. J Clin Oncol 1992; 10: 706-717.
3. McGuire WP, Hoskins WJ, Brady MF, et al.: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996; 334: 1-6.
4. Muggia FM, Braly PS, Brady MF, et al.: Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: A gynecologic oncology group study. J Clin Oncol 2000; 18: 106-115.
5. Ozols RF, Bundy BN, Greer BE, et al.: Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group study. J Clin Oncol 2003; 21: 3194-3200.
6. Alberts DS, Liu PY, Hannigan EV, et al.: Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 1996; 335: 1950-1955.
7. Markman M, Bundy BN, Alberts DS, et al.: Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: An intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 2001; 19: 1001-1007.
8. Armstrong DK, Bundy B, Wenzel L, et al.: Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006; 354: 34-43.
9. Lhomme C, Morice P, Planchamp F, et al.: Clinical practice guidelines 2008 for the surgical treatment, medical first-line and consolidation treatments of patients with epithelial ovarian cancer-Update. According to the methodology of Standards, Options: Recommendations (SOR). Bull Cancer 2008; 95: 881-886.
10. Witkamp AJ, de Bree E, Van Goethem R, et al.: Rationale and techniques of intra-operative hyperthermic intraperitoneal chemotherapy. Cancer Treat Rev 2001; 27: 365-374.
11. Fujimoto S, Takahashi M, Mutou T, et al.: Improved mortality rate of gastric carcinoma patients with peritoneal carcinomatosis treated with intraperitoneal hyperthermic chemoperfusion combined with surgery. Cancer 1997; 79: 884-891.
12. Witkamp AJ, de Bree E, Kaag MM, et al.: Extensive cytoreductive surgery followed by intra-operative hyperthermic intraperitoneal chemotherapy with mitomycin-C in patients with peritoneal carcinomatosis of colorectal origin. Eur J Cancer 2001; 37: 979-984.
13. Sugarbaker PH,: A curative approach to peritoneal carcinomatosis from colorectal cancer. Semin Oncol 2005; 32: S68-S73.
14. Glehen O, Mohamed F, Gilly FN,: Peritoneal carcinomatosis from digestive tract cancer: New management by cytoreductive surgery and intraperitoneal chemohyperthermia. Lancet Oncol 2004; 5: 219-228. (Pubitemid 38391217)
15. Los G, Verdegaal EM, Mutsaers PH, et al.: Penetration of carboplatin and cisplatin into rat peritoneal tumor nodules after intraperitoneal chemotherapy. Cancer Chemother Pharmacol 1991; 28: 159-165.
16. Raspagliesi F, Kusamura S, Campos Torres JC, et al.: Cytoreduction combined with intraperitoneal hyperthermic perfusion chemotherapy in advanced/recurrent ovarian cancer patients: The experience of National Cancer Institute of Milan. Eur J Surg Oncol 2006; 32: 671-675.
17. Reichman TW, Cracchiolo B, Sama J, et al.: Cytoreductive surgery and intraoperative hyperthermic chemoperfusion for advanced ovarian carcinoma. J Surg Oncol 2005; 90: 51-56, discussion 6-8.
18. Piso P, Dahlke MH, Loss M, et al.: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from ovarian cancer. World J Surg Oncol 2004; 2: 21.
19. Zanon C, Clara R, Chiappino I, et al.: Cytoreductive surgery and intraperitoneal chemohyperthermia for recurrent peritoneal carcinomatosis from ovarian cancer. World J Surg 2004; 28: 1040-1045.
20. Ryu KS, Kim JH, Ko HS, et al.: Effects of intraperitoneal hyperthermic chemotherapy in ovarian cancer. Gynecol Oncol 2004; 94: 325-332.
21. Chatzigeorgiou K, Economou S, Chrysafis G, et al.: Treatment of recurrent epithelial ovarian cancer with secondary cytoreduction and continuous intraoperative intraperitoneal hyperthermic chemoperfusion (CIIPHCP). Zentralbl Gynakol 2003; 125: 424-429.
22. Elkas JC, Winter WE III, Chernofsky MR, et al.: A phase I trial of oxaliplatin and topotecan in recurrent ovarian carcinoma. Gynecol Oncol 2007; 104: 422-427.
23. Rietbroek RC, van de Vaart PJ, Haveman J, et al.: Hyperthermia enhances the cytotoxicity and platinum-DNA adduct formation of lobaplatin and oxaliplatin in cultured SW 1573 cells. J Cancer Res Clin Oncol 1997; 123: 6-12.
24. Pestieau SR, Belliveau JF, Griffin H, et al.: Pharmacokinetics of intraperitoneal oxaliplatin: Experimental studies. J Surg Oncol 2001; 76: 106-114.
25. Elias D, Bonnay M, Puizillou JM, et al.: Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: Pharmacokinetics and tissue distribution. Ann Oncol 2002; 13: 267-272. (Pubitemid 34704979)
26. Fagotti A, Paris I, Grimolizzi F, et al.: Secondary cytoreduction plus oxaliplatin-based HIPEC in platinum-sensitive recurrent ovarian cancer patients: A pilot study. Gynecol Oncol 2009; 113: 335-340.
27. Sugarbaker PH,: Peritonectomy procedures. Ann Surg 1995; 221: 29-42.
28. Harmon RL, Sugarbaker PH,: Prognostic indicators in peritoneal carcinomatosis from gastrointestinal cancer. Int Semin Surg Oncol 2005; 2: 3.
29. Clavien P, Sanabria J, Strasberg S,: Proposed classification of complication of surgery with examples of utility in cholecystectomy. Surgery 1992; 111: 518-526.
30. Trotti A, Colevas AD, Setser A, et al.: CTCAE v3.0: Development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003; 13: 176-182.
31. Therasse P, Arbuck SG, Eisenhauer EA, et al.: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
32. Rustin GJ, Timmers P, Nelstrop A, et al.: Comparison of CA-125 and standard definitions of progression of ovarian cancer in the intergroup trial of cisplatin and paclitaxel versus cisplatin and cyclophosphamide. J Clin Oncol 2006; 24: 45-51.
33. Fader AN, Rose PG,: Role of surgery in ovarian carcinoma. J Clin Oncol 2007; 25: 2873-2883.
34. Glehen O, Kwiatkowski F, Sugarbaker PH, et al.: Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: A multi-institutional study. J Clin Oncol 2004; 22: 3284-3292.
35. de Bree E, Romanos J, Michalakis J, et al.: Intraoperative hyperthermic intraperitoneal chemotherapy with docetaxel as second-line treatment for peritoneal carcinomatosis of gynaecological origin. Anticancer Res 2003; 23: 3019-3027.
36. Fujimura T, Yonemura Y, Fujita H, et al.: Chemohyperthermic peritoneal perfusion for peritoneal dissemination in various intra-abdominal malignancies. Int Surg 1999; 84: 60-66.
37. Kober F, Heiss A, Roka R,: Diffuse and gross peritoneal carcinomatosis treated by intraperitoneal hyperthermic chemoperfusion. Cancer Treat Res 1996; 82: 211-219.
38. Rufian S, Munoz-Casares FC, Briceno J, et al.: Radical surgery-peritonectomy and intraoperative intraperitoneal chemotherapy for the treatment of peritoneal carcinomatosis in recurrent or primary ovarian cancer. J Surg Oncol 2006; 94: 316-324.
39. Kecmanovic DM, Pavlov MJ, Kovacevic PA, et al.: Cytoreductive surgery for ovarian cancer. Eur J Surg Oncol 2003; 29: 315-320.
40. van der Vange N, van Goethem AR, Zoetmulder FA, et al.: Extensive cytoreductive surgery combined with intra-operative intraperitoneal perfusion with cisplatin under hyperthermic conditions (OVHIPEC) in patients with recurrent ovarian cancer: A feasibility pilot. Eur J Surg Oncol 2000; 26: 663-668.
41. Hadi R, Saunders V, Utkina O, et al.: Review of patients with peritoneal malignancy treated with peritonectomy and heated intraperitoneal chemotherapy. ANZ J Surg 2006; 76: 156-161.
42. Di Giorgio A, Naticchioni E, Biacchi D, et al.: Cytoreductive surgery (peritonectomy procedures) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of diffuse peritoneal carcinomatosis from ovarian cancer. Cancer 2008; 113: 315-325.
43. Bae JH, Lee JM, Ryu KS, et al.: Treatment of ovarian cancer with paclitaxel- or carboplatin-based intraperitoneal hyperthermic chemotherapy during secondary surgery. Gynecol Oncol 2007; 106: 193-200.
44. Cotte E, Glehen O, Mohamed F, et al.: Cytoreductive surgery and intraperitoneal chemo-hyperthermia for chemo-resistant and recurrent advanced epithelial ovarian cancer: Prospective study of 81 patients. World J Surg 2007; 31: 1813-1820.
45. Helm CW, Randall-Whitis L, Martin RS III, et al.: Hyperthermic intraperitoneal chemotherapy in conjunction with surgery for the treatment of recurrent ovarian carcinoma. Gynecol Oncol 2007; 105: 90-96.
46. Look M, Chang D, Sugarbaker PH,: Long-term results of cytoreductive surgery for advanced and recurrent epithelial ovarian cancers and papillary serous carcinoma of the peritoneum. Int J Gynecol Cancer 2004; 14: 35-41.
47. Deraco M, Rossi CR, Pennacchioli E, et al.: Cytoreductive surgery followed by intraperitoneal hyperthermic perfusion in the treatment of recurrent epithelial ovarian cancer: A phase II clinical study. Tumori 2001; 87: 120-126.
48. Rubin SC, Randall TC, Armstrong KA, et al.: Ten-year follow-up of ovarian cancer patients after second-look laparotomy with negative findings. Obstet Gynecol 1999; 93: 21-24.
49. Bijelic L, Jonson A, Sugarbaker PH,: Systematic review of cytoreductive surgery and heated intraoperative intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis in primary and recurrent ovarian cancer. Ann Oncol 2007; 18: 1943-1950.
50. Verwaal VJ, van Ruth S, de Bree E, et al.: Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 2003; 21: 3737-3743.
51. Piccart MJ, Lacave AJ, Reed N, et al.: Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: A randomized phase II study of the European Organization for Research and Treatment of Cancer Gynecology group. J Clin Oncol 2000; 18: 1193-1202.
52. Ceelen WP, Van Nieuwenhove Y, Van Belle S, et al.: Cytoreduction and hyperthermic intraperitoneal chemoperfusion in women with heavily pretreated recurrent ovarian cancer. Ann Surg Oncol 2009; [Epub ahead of print].